Surgical Intervention in Patients with Metastatic Renal Cancer: Metastasectomy and Cytoreductive Nephrectomy

Urologic Clinics of North America

Volumn 35, Issue 4, 2008, Pages 679-686

  Russo, Paul ^a   O'Brien, Matthew Francis ^b  

^a Hospital for Special Surgery   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytoreductive; Kidney cancer; Metastasectomy; Renal cancer

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOKINE; EVEROLIMUS; FLUTAMIDE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN PEPTIDE COMPLEX 96; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY G250; N METHYLFORMAMIDE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; KIDNEY CANCER; METASTASIS; METASTECTOMY; MONOTHERAPY; NEPHRECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEPHRECTOMY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 55249093686     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2008.07.009     Document Type: Review

References (35)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
3. Bukowski R.M., and Wood L.S. Renal cell carcinoma: state of the art diagnosis and treatment. Clin Oncol 11 (2008) 9-21
4. O'Brien F., Motzer R., and Russo P. Sunitinib therapy in renal cell carcinoma. BJU Int 101 (2008) 1339-1342
5. Barney J.D., and Churchill E.J. Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol 42 (1939) 269-276
6. Giuliani L., Giberti C., Martorana G., et al. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143 (1990) 468-473
7. Golimbu M., Joshi P., Sperber A., et al. Renal cell carcinoma: survival and prognostic factors. Urology 27 (1986) 291-301
8. Maldazys J.D., and deKernion J.B. Prognostic factors in metastatic renal carcinoma. J Urol 136 (1986) 376-379
9. Neves R.J., Zincke H., and Taylor W.F. Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 139 (1988) 1173-1176
10. Pogrebniak H.W., Haas G., Linehan W.M., et al. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 54 (1992) 33-38
11. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8 (2007) 304-310
12. Kavolius J.P., Mastorakos D.P., Pavolvich C., et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 16 (1998) 2261-2266
13. Wronski M., Russo P., Galicich J., et al. Surgical resection of brain metastases from renal cell carcinoma. Urology 47 (1996) 187-193
14. Kim S.H., Brennan M.F., and Russo P. The role of surgery in the treatment of adrenal metastasis. Cancer 82 (1998) 389-394
15. Russo P., Snyder M., Vickers A., et al. Cytoreductive neprhectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. The Scientific World Urology 2 (2007) 42-52
16. Montie J.E., Stewart B.H., Straffon R.A., et al. The role of adjuvant nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117 (1977) 272-275
17. Walther M.M., Yang J.C., Pass H.I., et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158 (1997) 1675-1678
18. Rackley R., Novick A., Klein E., et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152 (1994) 1399-1403
19. Sella A., Swanson D.A., Ro J.Y., et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 149 (1993) 19-21
20. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa 2-b compared with interferon alfa-2b alone for metastatic renal cell carcinoma. N Engl J Med 345 (2001) 1655-1659
21. Mickisch G.H., von Poppel H., de Prijck L., et al. Radical nephrectomy plus interferon-alfa based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 358 (2001) 966-970
22. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive npherectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
23. Bromwich E., Hendry D., and Aitchison M. Cytoreductive nephrectomy: Is it a realistic option in patients with renal cancer. BJU Int 89 (2002) 523-525
24. Fossa S.D. Interferon in metastatic renal cell carcinoma. Semin Oncol 27 (2000) 187-193
25. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2859-2867
26. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
27. Kattan M.W., Reuter V.E., Motzer R.J., et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001) 63-67
28. Lee C.T., Katz J., Fearn P.A., et al. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 7 (2002) 135-140
29. Eggener S.E., Yossepowitch O., Pettus J.A., et al. Renal cell carcinoma recurrence after nephrectomy for localized disease. Predicting survival from time of recurrence. J Clin Oncol 24 (2006) 3101-3131
30. Eggener S.E., Yossepowitch O., Kudhu S., et al. Objective (risk stratification) and subjective (metastasectomy) factors impact prognosis in patients with recurrent renal cell carcinoma following nephrectomy. J Urol 180 3 (2008) 873-878
31. Iliopoulous O., Levy A.P., Jiang C., et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93 (1996) 10595-10599
32. Wykoff C.C., Beasley N.J., Watson P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60 (2000) 7075-7083
33. Beck S.D., Patel M.I., Snyder M.E., et al. Renal cortical tumors: variable metastatic potential. Ann Surg Oncol (2004) 11:71-7
34. Motzer R.J., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 20 (2002) 2376-2381
35. Margulis V., Matin S.F., Tannir N., et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180 (2008) 94-98